The actions of luteinizing hormone-releasing hormone agonists, antagonists, and cytotoxic analogues on the luteinizing hormone-releasing hormone receptors on the pituitary and tumors

Infertility and Reproductive Medicine Clinics of North America

Volumn 12, Issue 1, 2001, Pages 17-44

  Schally, A V ^a   Halmos, G ^a   Rekasi, Z ^a   Arencibia Jimenez, J M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; GONADORELIN; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; GONADOTROPIN; MESSENGER RNA; SEX HORMONE;

BREAST CANCER; CANCER INHIBITION; CASTRATION; CYTOTOXICITY; ENDOMETRIUM CANCER; GONADOTROPIN RELEASE; HORMONE ACTION; LUTEINIZING HORMONE RELEASE; OVARY CANCER; PROSTATE CANCER; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; TUMOR GROWTH;

EID: 0035182258     PISSN: 10479422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation
2. Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line
3. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues
4. GnRH receptor mRNA, GnRH and GnRH mRNA responses to castration and testosterone replacement in the male rat
5. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men
6. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone
7. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75)
8. Hypothalamic regulation of pituitary gonadotropin-releasing hormone receptors: Effects of hypothalamic lesions and a gonadotropin-releasing hormone antagonist
9. Efficacy and safety of luteinizing hormone-releasing hormone antagonist Cetrorelix in the treatment of symptomatic benign prostatic hyperplasia
10. Gonadotropin-releasing hormone and its analogues
11. Conversion of a gonadotropin-releasing hormone antagonist to an agonist
12. Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6
13. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation
14. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine-inhibitory LHRH loop
15. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists
16. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells
17. High affinity binding and direct antiproliferative effects of LH-RH analogues in human ovarian cancer cell lines
18. Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells
19. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers
20. High affinity binding and direct antiproliferative effects of LH-RH analogues in human endometrial cancer cell lines
21. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer
22. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix
23. Synthetic analogs of luteinizing hormone-releasing hormone (LHRH) substituted in positions 6 and 10
24. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix
25. Luteinizing hormone-releasing hormone antagonist SB-75 (Cetrorelix) as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord
26. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)
27. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer
28. Evolving role of gonadotropin-releasing hormone antagonists
29. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers
30. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high-affinity to human breast cancers
31. Down-regulation and translocation of receptors for luteinizing hormone-releasing hormone (LH-RH) in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix
32. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix
33. Subcellular translocation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix
34. Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines
35. Assessment of the role of G proteins and inositol phosphate production in the action of gonadotropin-releasing hormone
36. Pituitary receptor site blockade by a gonadotropin-releasing hormone antagonist in vivo: Mechanism of action
37. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factor
38. Expression of the messenger ribonucleic acids for luteinizing hormone-releasing hormone and its receptor in human ovarian epithelial carcinoma
39. Expression of luteinizing hormone-releasing hormone and its mRNA in human endometrial cancer cell lines
40. LH-RH antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice
41. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by LH-RH antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
42. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin
43. Complete regression of MX-1 human breast cancer xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207
44. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice
45. Regulation of rat pituitary gonadotropin-releasing hormone receptor mRNA levels in vivo and in vitro
46. Molecular structure of the human gonadotropin-releasing hormone receptor gene
47. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary
48. The inhibition of growth and down-regulation of gonadotropin releasing hormone (GnRH) receptor in αT3-1 cells by GnRH agonist
49. Gonadotropin-releasing hormone analog design: Structure-function studies toward the development of agonists and antagonists. Rationale and perspective
50. Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis
51. Regulation of endometrial cancer cell growth by insulin-like growth factors and luteinizing hormone-releasing hormone antagonist SB-75
52. Hormonal responses to the new potent GnRH antagonist Cetrorelix
53. The neuroendocrine control of the menstrual cycle
54. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice
55. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone
56. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice
57. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors
58. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II tumors
59. Expression of gonadotropin-releasing hormone (GnRH) receptor gene is altered by GnRH agonist desensitization in a manner similar to that of gonadotropin β-subunit genes in normal and castrated rat pituitary
60. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP
61. Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP
62. Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
63. Homologous regulation of gonadotropin-releasing hormone receptors in cultured pituitary cells
64. Receptor-binding properties of gonadotropin-releasing hormone derivatives
65. Homologous down-regulation of gonadotropin-releasing hormone receptor sites and messenger ribonucleic acid transcripts in αT3-1 cells
66. Synthesis of the porcine LH- and FSH-releasing hormone by the solid-phase method
67. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence
68. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist
69. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone
70. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice
71. Suppression of plasma gonadotropins by Abarelix: A potent new LHRH antagonist
72. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500- 1000 times more potent
73. 2+ mobilizing hormones: The case of gonadotropin-releasing hormone
74. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)
75. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day eight of in vitro fertilization cycles: A pilot study
76. Gonadotropin gene expression and secretion in gonadotropin-releasing hormone antagonist-treated male rats: Effect of sex steroid replacement
77. Chronic administration of luteinizing hormone-releasing hormone (LHRH) antagonist Cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats
78. Comparison of biological effects of a sustained delivery system and nonecapsulated LH-RH antagonist SB- 75 in rats
79. The effect of gonadotrophin-releasing hormone analogues in prostate cancer are mediated through specific tumour receptors
80. Sustained-release formulations of LH-RH antagonist SB-75 inhibit proliferation and enhance the apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice
81. Cetrorelix
82. Development and applications of LHRH antagonists in the treatment of infertility - An overview
83. The LHRH-antagonist Cetrotide, (Cetrorelix): A review
84. Effect of a cytotoxic analog (AN-207) of luteinizing hormone-releasing hormone (LHRH) on mRNA expression of receptors for LHRH and growth hormone-releasing hormone and secretion of LH and GH from pituitary cells in ovariectomized rats
85. Effects of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone (LHRH) on LH secretion and gene expression for LH β-subunit and LHRH receptors in superfused rat pituitary cells
86. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on the function of rat pituitary cells: Tests in a long term superfusion system
87. Pituitary gonadotropins inhibition by a highly active analog of luteinizing hormone-releasing hormone
88. The use of LHRH analogs in gynecology and tumor therapy
89. LH-RH analogues. I. Their impact on reproductive medicine
90. Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis
91. Purification and properties of the LH and FSH-releasing hormone from procine hypothalami
92. Isolation and properties of the FSH- and LH-releasing hormone
93. Gonadotropin-releasing hormone: One polypeptide regulates secretion of luteinizing and follicle-stimulating hormones
94. Analogs of LHRH: The present and the future
95. Hypothalamic and other peptide hormones
96. Antagonistic analogs of LHRH in oncology and gynecology
97. Stimulation and inhibition of fertility through hypothalamic agents
98. Hypothalamic FSH and LH-regulating hormone, structure, physiology, and clinical studies
99. FSH-releasing hormone and LH-releasing hormone
100. Edward T. Tyler Prize Oration - LH-releasing hormone and its analogues: Recent basic and clinical investigations
101. The privileges of a Nobel Laureate
102. Chemotherapy targeted to hormone receptors on tumors: Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
103. LH-RH analogs with cytotoxic radicals
104. Isolation of the LH- and FSH-releasing hormone from porcine hypothalami
105. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells
106. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone
107. Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice
108. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75
109. 6]-luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer
110. 6]-LH-RH and EGF in human endometrial carcinoma
111. Expression and signal transduction pathways of gonadotropin-releasing hormone receptors
112. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75
113. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination
114. Targeted cytotoxic luteinizing hormone-releasing hormone (LH-RH) analogs inhibit growth of estrogen-independent MXT mouse mammary cancer in vivo by decreasing cell proliferation and inducing apoptosis
115. Exogenous gonadotrophin-releasing hormone (GnRH) stimulates LH secretion in male monkeys (Macacafascicularis) treated chronically with high doses of a GnRH-antagonist
116. A chemically labeled cytotoxic agent: Two-photon fluorophore for optical tracking of cellular pathway in chemotherapy
117. Gonadal hormones and gonadotropin-releasing hormone (GnRH) alter messenger ribonucleic acid levels for GnRH receptors in sheep
118. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH
119. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75
120. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone